GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors
Retrieved on:
Monday, April 10, 2023
Pancreatic cancer, CIN, BMC, Oncology, DNA, VEGFA, Samsung Medical Center, Genome instability, Nucleic acid thermodynamics, Hepatocellular carcinoma, Sorafenib, CAP, Neoplasm, Survival, University, Cancer, Head, Research, Attention, Genome, Biomarker, Lung, Infant, Plasma, Rare, SM, Patient, Basel, Esophageal cancer, SY, Sungkyunkwan University, Chemoradiotherapy, RT, GC, Disease, Medical imaging, Vaccine, MD
This study adds to the previous studies of prognostic effects of the I-score in various solid tumors, including hepatocellular carcinoma, esophageal cancer, and pancreatic adenocarcinoma1.2.3.
Key Points:
- This study adds to the previous studies of prognostic effects of the I-score in various solid tumors, including hepatocellular carcinoma, esophageal cancer, and pancreatic adenocarcinoma1.2.3.
- Another interesting finding is that minimal residual disease following RT was detected earlier by cfDNA than by imaging studies.
- "Further additional studies are ongoing to optimize the measurement and analysis of I-scores to predict radiation response accurately.
- Such statements do not represent any guarantee by GC Genome or its management of future performance and involve known and unknown risks, uncertainties and other factors.